广州万孚生物技术股份有限公司董事会 公司债权人如要求公司清偿债务或提供相应担保的，应根据《中华人民共和国公司法》等相关法律法规 的规定，向公司提出书面要求，并附随有关证明文件。如债权人未在规定期限内行使上述权利的，公司 本次回购注销限制性股票将按法定程序继续实施。 特此公告。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。 2025年7月4日，广州万孚生物技术股份有限公司（以下简称"公司"）召开2025年第一次临时股东大会， 审议通过了《关于终止实施 2024 年限制性股票激励计划暨回购注销限制性股票的议案》，因公司经营 所面临的内外部环境与制定股权激励计划时相比发生了较大变化，导致公司预期经营情况与激励方案考 核指标的设定存在偏差，继续推进和实施激励计划难以达到对激励对象的激励效果。经公司董事会审慎 考虑后，决定终止实施 2024 年限制性股票激励计划，并回购注销公司 2024 年限制性股票激励计划所涉 及的已授予但尚未解除限售的限制性股票 1054.40 万股，同时与之配套的《2024 年限制性股票激励计划 实施考核管理办法》等相关文件一并终止。具体内容详见公司 ...

Core Insights - Bawei Co., Ltd. reported a significant increase in both revenue and net profit for the year 2024, with total revenue reaching approximately 695 million yuan, a year-on-year increase of 48.27%, and a net profit attributable to shareholders of 45.39 million yuan, reflecting a growth of 10.28% [3] Executive Compensation - Among the disclosed executive compensations, the company secretary, Dan Nan, experienced a salary decrease to 649,200 yuan, down by 77,700 yuan from the previous year, making it one of the lowest among the management team [3] - In contrast, the chairman, Leng Qunying, saw his compensation rise to 1.637 million yuan, an increase of 557,000 yuan; the vice president, Leng Zhigang, received 1.038 million yuan, up by 316,500 yuan; and another vice president, Chen Biao, earned 1.434 million yuan, an increase of 514,000 yuan [3] Company Structure - Bawei Co., Ltd. is characterized as a typical family-run enterprise, with significant family ties among the executive team. The chairman, Leng Qunying, previously worked as a middle school teacher for nearly eight years, and his spouse, Liu Ruixue, currently serves as a director and holds 10.8 million shares [3][4] - The company secretary, Dan Nan, is the son-in-law of Leng Qunying and Liu Ruixue, holding 2.116 million shares [4]

Group 1 - Shougang Longze has delayed its global offering and listing due to a civil lawsuit filed against it, which requires the company to provide more information to investors [1] - The company plans to issue a supplementary prospectus to update the listing timeline and related information [1] Group 2 - Hong Kong Stock Exchange has launched an order transmission service for its Integrated Fund Platform (IFP) to enhance efficiency in the fund distribution ecosystem [2] - The service integrates order processing for fund subscriptions and redemptions, welcoming 33 initial participants including distributors and fund companies [2] Group 3 - Eye care biotech company Bokan Vision Cloud-B saw its stock price drop significantly on its first trading day, closing down 38.61% from its IPO price of 10.1 HKD [3] - The decline may be attributed to market skepticism regarding its valuation and the current market environment for new listings [3] Group 4 - Anjoy Foods had a lackluster performance in the dark market, with its H-shares priced at 60 HKD and a total global offering of approximately 39.99 million shares [4] - Despite being the largest frozen food company in China with a market share of 6.6%, investor concerns about growth prospects and market competition may have impacted its initial reception [4]

受一系列超预期的宏观数据推动，北京时间7月3日晚间，美股三大指数集体高开高走，截至收盘，纳指涨1.02%，标普500指数涨0.83%，道指 涨0.77%。 标普500指数创下年内第七次历史收盘新高，纳指则创下年内第四次历史收盘新高。 美股大型科技股亦全线上涨，英伟达涨超1.3%，收于历史新高，盘中一度涨超2%，盘中总市值最高达到3.92万亿美元。 值得一提的是，在美上市的中概股公司——脑再生科技再度爆发，盘中一度暴涨超170%，多次触及熔断，该股年内涨幅达213倍，成为2025年 美股表现最亮眼的"妖股" 之一。 | W | | | 脑再生 | | | | | --- | --- | --- | --- | --- | --- | --- | | RGC.O | | | | | | | | 22.990 量 1879.6万 股本 4.94亿 | | | | | 市盈 -2643 | 万得 | | 12.630 121.91% 換 3.79% 市值1 114亿 | | | | | 市净 1383 | 图口 | | 盯盘 因独立日假期,美股于7月4日休市 | | | | | | | | 盘后 19.840 -3. ...

● 本报记者 黄一灵 A股上市公司正扎堆赴港上市。据不完全统计，自去年9月以来，前往港交所成功上市的A股上市公司已 有10家。同时，后备队伍持续扩容，还有数十家A股上市公司正筹划赴港上市。 被誉为"东北药茅"的长春高新7月1日晚亦发布公告称，公司拟在境外发行股份（H股）并在香港联交所 上市，公司董事会授权公司管理层启动本次H股上市的前期筹备工作。长春高新表示，拟赴港上市，旨 在深化公司全球化战略布局，加快国际化进程，增强公司在境外的融资能力，进一步提升公司国际品牌 形象。 以上案例是近期A股上市公司扎堆赴港IPO的一个缩影。以科技类公司为例，华泰证券研报数据显示， 截至6月30日，2025年已有包括蓝思科技、龙旗科技等在内的16家A股半导体/消费电子公司提交了港股 招股书，数量显著高于2024年同期水平。 自去年9月以来，已有10家A股上市公司在港交所上市，其中多是A股龙头公司，例如宁德时代、恒瑞医 药、海天味业等。 政策护航 A股优质公司纷纷赴港上市离不开政策护航。 从赴港IPO原因来看，全球化成为关键词。更为重要的是，因为有A股上市地位，这些公司的价值在港 股市场也能更好地被发现，从而被合理定价。此外，业 ...

General Provisions - The document outlines the information disclosure deferral and exemption management system for Guangzhou Jiete Biological Filtration Co., Ltd, aiming to ensure compliance with relevant laws and regulations [2][3] - The term "information disclosure obligor" includes the company, its directors, general manager, financial officer, board secretary, and other senior management personnel, as well as major responsible persons from departments and subsidiaries [2] Scope of Deferral and Exemption - Information disclosure obligors can defer disclosure if the information is uncertain or involves temporary business secrets, and timely disclosure may harm the company's interests or mislead investors [3][4] - Exemptions from disclosure apply to state secrets, commercial secrets, and sensitive business information that could violate confidentiality laws or harm the interests of the company and investors [3][4] Procedures for Deferral and Exemption - Information disclosure obligors must carefully determine deferral and exemption matters and take effective measures to prevent leaks of deferred or exempted information [5][6] - The securities department is responsible for organizing and coordinating the specific affairs related to deferral and exemption of information disclosure [5] Responsibilities of Information Disclosure Obligors - Information disclosure obligors must ensure that the information proposed for deferral or exemption is true, accurate, and complete, without any misleading statements or omissions [6][7] - If deferred or exempted information is leaked or if the reasons for deferral or exemption are eliminated, the company must verify the situation and disclose the information promptly [6][7] Reporting and Documentation - After the annual, semi-annual, or quarterly reports are announced, the company must submit relevant registration materials regarding deferred or exempted disclosures to the local securities regulatory authority and stock exchange within ten days [7][8] - The document includes templates for registration and confidentiality commitments related to deferred or exempted disclosures [10]

Core Viewpoint - The Shanghai Meino Biological Technology Co., Ltd. has proposed a restricted stock incentive plan for 2025, which has been reviewed and deemed eligible for implementation by the Board of Directors' Compensation and Assessment Committee [1][3]. Group 1: Eligibility and Compliance - The company meets the qualifications to implement the stock incentive plan as there have been no negative or unqualified audit opinions on the financial reports for the last accounting year [1]. - The incentive plan does not include independent directors, and all selected incentive objects comply with the conditions set forth in the relevant regulations [2]. Group 2: Disclosure and Approval Process - The company is required to publicly disclose the names and positions of the incentive objects for at least 10 days prior to the shareholders' meeting [3]. - The plan's details, including grant arrangements and conditions, must be reviewed and approved by the shareholders' meeting before implementation [3]. Group 3: Objectives and Benefits - The incentive plan aims to align the interests of employees and shareholders, enhance management efficiency, and support the sustainable development of the company [3].

美股"妖股"狂飙。 受一系列超预期的宏观数据推动，美股三大指数全线走强，纳指、标普500指数盘中均创出历史新高，道指逼 近历史新高。其中，脑再生科技再度爆发，盘中一度暴涨超170%，多次触及熔断。 有分析称，最新发布的一系列宏观数据缓解了市场对美国经济增速放缓的担忧。其中，美国6月非农就业数据 预示着美国劳动力市场仍具备较强的韧性。另外，美国6月ISM非制造业指数报50.8，略高于预期。 与此同时，美国与欧盟的关税谈判也传来最新消息。美国财长贝森特称，今天与欧盟谈判代表会面。欧盟委员 会主席冯德莱恩则表示，欧盟希望在下周的最后期限前与美国达成一项原则性的贸易协议。 受独立日休假影响，今夜美股将提前3小时于北京时间周五凌晨1点休市（盘后交易时段为1点至5点），周五全 天休市。 全线大涨 北京时间7月3日晚间，美股三大指数集体高开高走，截至23:00，纳指涨0.97%，标普500指数涨0.81%，均创出 历史新高；道指涨0.83%，逼近历史新高。 美股大型科技股亦全线上涨，英伟达一度涨超2%，盘中总市值最高达到3.92万亿美元；微软、亚马逊、博 通、台积电ADR均涨超1%。 值得一提的是，在美上市的中概股公司—— ...

Group 1 - Major industry ETFs in the US stock market experienced an overall increase, with regional bank ETFs rising by 1.59%, global airline ETFs by 1.51%, and bank ETFs by 1.27% [1][2] Group 2 - Regional bank ETF (KRE) is currently priced at $63.51, with a gain of $0.99 (+1.59%) and a total market value of $5.3 billion, reflecting a year-to-date increase of 6.66% [2] - Global airline ETF (JETS) is priced at $24.15, up by $0.36 (+1.51%), with a market value of $760.725 million, showing a year-to-date decline of 4.73% [2] - Bank ETF (KBE) is trading at $59.00, gaining $0.74 (+1.27%), with a market capitalization of $4.567 billion and a year-to-date increase of 7.86% [2]

Company Formation - Beisai Hongsheng (Chengdu) Biotechnology Co., Ltd. has been established with a registered capital of 100 million RMB [1] - The legal representative of the company is Zhang Yi, and it is wholly owned by Beifan Ru Hai Biotechnology (Shanghai) Co., Ltd. [1] Business Scope - The business scope includes technology services, development, consulting, and transfer, as well as sales of medical devices, software development, import and export of goods and technology, and research and development in various scientific fields [2] - The company is classified under the national standard industry of scientific research and technical services, specifically focusing on engineering and technical research and development [2] Company Structure - Beisai Hongsheng is categorized as a limited liability company (wholly foreign-owned enterprise) [2] - The company is registered in Chengdu, Sichuan Province, with an operational period extending until an indefinite date [2]